摘要
总结了更昔洛韦防治肾移植患者巨细胞病毒（Ｃｙｔｏｍｅｇａｌｏｖｉｒｕｓ，ＣＭＶ）感染的研究结果。预防研究共１５３例，更昔洛韦组８８例，阿昔洛韦组６５例。两组预防ＣＭＶ疾病的效果有明显差异（９．１％ｖｓ２４．６％，Ｐ＜０．０５），而预防ＣＭＶ活动性感染的效果无明显差异（２０．４％ｖｓ１５．６％，Ｐ＞０．０５），但更昔洛韦组ＣＭＶ活动性感染的持续时间明显短于阿昔洛韦组（２～６周ｖｓ３～９周，Ｐ＜０．０１）。治疗ＣＭＶ肺炎３１例，更昔洛韦组１５例治愈率８０％；阿昔洛韦组１６例治愈率２５％（Ｐ＜０．０５）。认为更昔洛韦能有效预防ＣＭＶ疾病，缩短活动性感染的持续时间，对ＣＭＶ疾病有比较满意的治疗效果。
This article has summarized the comparison research result of Ganciclovir (GCV) preventing and treating infections of CMV (cytomegalovirus) in cadaveric renal transplantation.In 153 cases of prevention research,88 were in GCV group and 65 in ACV group;the morbidity of CMV disease was 9.1% and 24.6% respectively (P<005). The duration of active infection in GCV and ACV group was 2￣6 weeks and 3￣9 weeks respectively (P<0.01).In 31 cases of pulmonary CMV infection, the cured rate was 80% in 15 patients with GCY, and 25% in 16 with ACV (P<0.05).It is convinced that GCV could prevent and treat CMV diseases satisfactorily,decurate the duration of static infection.
出处
《西安医科大学学报》
CSCD
1999年第2期178-181,共4页
Journal of Xi'an Medical University(Chinese)
基金
陕西省卫生厅科学研究基金
关键词
巨细胞病毒感染
防治
肾移植
更昔洛韦
cytomegalovirus (CMV)
prevention
treatment
transplantation
ganciclovir
aeyclovir
